Literature DB >> 17273911

Plasma concentrations, pharmacokinetics and urinary excretion of gatifloxacin after single intravenous injection in buffalo calves.

M Raipuria1, V K Dumka, H S Sandhu.   

Abstract

The pharmacokinetics and urinary excretion of gatifloxacin were investigated after a single intravenous injection of 4 mg/kg body weight in buffalo calves. The therapeutic plasma drug concentration was maintained for up to 12 h. Gatifloxacin rapidly distributed from blood to tissue compartments, which was evident from the high values of the distribution rate constant, alpha1 (11.1 +/- 1.06 h(-1)) and the rate constant of transfer of drug from central to peripheral compartment, k12 (6.29 +/- 0.46 h(-1)). The area under the plasma drug concentration-time curve and apparent volume of distribution were 17.1 +/- 0.63 (microg.h)/ml and 3.56 +/- 0.95 L/kg, respectively. The elimination half-life (t (1/2 beta)), total body clearance (ClB) and the ratio of drug present in tissues and plasma (T/P) were 10.4 +/- 2.47 h, 235.1 +/- 8.47 ml/(kg.h) and 10.1 +/- 2.25, respectively. About 19.7% of the administered drug was excreted in urine within 24 h. A satisfactory intravenous dosage regimen for gatifloxacin in buffalo calves would be 5.3 mg/kg at 24 h intervals.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17273911     DOI: 10.1007/s11259-007-3343-7

Source DB:  PubMed          Journal:  Vet Res Commun        ISSN: 0165-7380            Impact factor:   2.816


  17 in total

Review 1.  Pharmacokinetics and pharmacodynamics of fluoroquinolones.

Authors:  K A Rodvold; M Neuhauser
Journal:  Pharmacotherapy       Date:  2001-10       Impact factor: 4.705

2.  Interchangeability of 400-mg intravenous and oral gatifloxacin in healthy adults.

Authors:  F P LaCreta; S Kaul; G D Kollia; G Duncan; D M Randall; D M Grasela
Journal:  Pharmacotherapy       Date:  2000-06       Impact factor: 4.705

3.  Age and gender effects on the pharmacokinetics of gatifloxacin.

Authors:  F P LaCreta; G D Kollia; G Duncan; D Behr; D M Grasela
Journal:  Pharmacotherapy       Date:  2000-06       Impact factor: 4.705

4.  Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans.

Authors:  M Nakashima; T Uematsu; K Kosuge; H Kusajima; T Ooie; Y Masuda; R Ishida; H Uchida
Journal:  Antimicrob Agents Chemother       Date:  1995-12       Impact factor: 5.191

5.  Outline of details for microbiological assays of antibiotics: second revision.

Authors:  B Arret; D P Johnson; A Kirshbaum
Journal:  J Pharm Sci       Date:  1971-11       Impact factor: 3.534

Review 6.  Gatifloxacin: a review of its use in the management of bacterial infections.

Authors:  Caroline M Perry; Douglas Ormrod; Miriam Hurst; Susan V Onrust
Journal:  Drugs       Date:  2002       Impact factor: 9.546

7.  Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models.

Authors:  D Andes; W A Craig
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

8.  Concentrations of gatifloxacin in plasma and urine and penetration into prostatic and seminal fluid, ejaculate, and sperm cells after single oral administrations of 400 milligrams to volunteers.

Authors:  C K Naber; M Steghafner; M Kinzig-Schippers; C Sauber; F Sörgel; H J Stahlberg; K G Naber
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

9.  Antimicrobial susceptibilities of 40 isolates of Bacillus anthracis isolated in Turkey.

Authors:  Duygu Esel; Mehmet Doganay; Bulent Sumerkan
Journal:  Int J Antimicrob Agents       Date:  2003-07       Impact factor: 5.283

Review 10.  The fluoroquinolones: how long will their utility last?

Authors:  Johan S Bakken
Journal:  Scand J Infect Dis       Date:  2004
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.